Interpace Diagnostics Participates in USA Today Endocrine Health Campaign

PARSIPPANY, N.J., March 20, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced its participation in a major awareness campaign on Endocrine Health published in a special insert in the March 17-19^th edition of USA Today in several key markets including New York, Los Angeles, Dallas, South Florida, and New Orleans. The information from the campaign is also available on the following digital site: http://www.futureofpersonalhealth.com/

Interpace has joined with other key organizations including the American Thyroid Association, the Endocrine Society, and the NIH in a campaign that encourages readers to pay attention to the signs that often lead to the diagnosis of a disorder, like thyroid cancer, and also provides readers with the available solutions to assist them in preventing illness and managing their overall endocrine health. Although most people rarely think about their endocrine system, it influences almost every cell, organ, and function of the body.  By playing a role in regulating mood, growth and development, tissue function, metabolism, and sexual function and reproductive processes, the health of this system is vital to an individual's overall health status.

Currently, over 20 million Americans are living with some form of endocrine disorder, yet 60% of them are unaware. Through Interpace's support, the campaign will raise readers' awareness of the importance of the endocrine system and educate them on the most common health issues and disorders that are influenced by the system, including thyroid nodule growth, an increasingly common diagnosis, particularly among younger women.   As a provider of molecular testing for patients with indeterminate thyroid nodules who are concerned they may have Thyroid cancer, Interpace serves an important role in both educating patients and providing important diagnostic insights to ensure their physicians have all the information needed to make the best treatment decisions. 

ThyGenX®, Interpace's mutational panel for indeterminate thyroid nodules, and ThyraMIR®, the Company's micro RNA based classifier, both provide Endocrinologists insights that assist them in determining whether or not a surgical procedure to remove part or all of the thyroid gland is appropriate.  These tests are used when standard cytological evaluation is indeterminate for cancer.  Interpace has performed over 15,000 cases of ThyGenX and ThyraMIR since they were launched in 2014 and 2015 respectively.  Over 400 Endocrinologists, Pathologists, and ENT's have used the tests nationwide. 

Jack Stover, President and CEO of Interpace Diagnostics stated, "We are pleased that USA Today included us in this important educational program.  As a provider of molecular testing for thyroid cancer, this is consistent with our commitment to educate both physicians and patients about the best options available to them."

About Thyroid Nodules, ThyGenX and ThyraMIR testing

According to the American Thyroid Association, approximately 15% to 30% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGenX and ThyraMIR.

ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.  The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. ThyraMIR is the first microRNA gene expression classifier.  MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs.  Both ThyGenX and ThyraMIR are covered by both Medicare and Commercial insurers. 

About Interpace Diagnostics Group, Inc.

Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics' website at www.interpacediagnostics.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to our future financial and operating performance. The company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.  These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to adequately finance the business, our ability to restructure our debt and other obligations, our ability to find a buyer of our assets, the market's acceptance of our molecular diagnostic tests; our ability to secure additional business and generate higher profit margins through sales of our molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company's periodic filings with the Securities and Exchange Commission (SEC), including without limitation, the Annual Report on Form 10-K filed with the SEC on March 30, 2016 as amended on April 29, 2016 and June 14, 2016, and the Quarterly Report on Form 10-Q filed with the SEC on November 17, 2016. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:
Interpace Diagnostics
Investor Relations:
Paul Kuntz – Redchip
[email protected]

SOURCE Interpace Diagnostics Group, Inc.

Related Links

http://www.interpacediagnostics.com